IJOHNS  Vol.5 No.2 , March 2016
Role of Intratympanic Steroids in the Management of Meniere’s Disease—A Review of 151 Cases
Abstract: Objective: To assess the outcomes of hearing and vertigo in patients with Meniere’s disease who were treated with intratympanic methylprednisolone. Study Design: Retrospective study. Setting: Tertiary referral hospital. Methods: In our study with 151 patients [191 ears] were diagnosed as Menieres as per 1995 AAO-HNS guidelines. As an office based procedure these patients were treated with intratympanic methyl prednisolone. Results: There was a 98.6% improvement in the vertigo control rate, a 73.82% improvement in hearing and 29.31% had a definitive improvement in tinnitus. Conclusion: We conclude from our study that intratympanic steroid injection significantly controls vertigo, tinnitus and improves hearing in Meniere’s disease with minimal complications. Hence, it can be tried as a first line treatment for patients with Meniere’s disease.
Cite this paper: Deenadayal, D. , Vidyasagar, D. , Bommakanti, V. , Goel, K. and Naeem, N. (2016) Role of Intratympanic Steroids in the Management of Meniere’s Disease—A Review of 151 Cases. International Journal of Otolaryngology and Head & Neck Surgery, 5, 108-113. doi: 10.4236/ijohns.2016.52018.

[1]   Plontke, S.K. and Gürkov, R. (2015) Menière’s Disease. Laryngo-Rhino-Otologie, 94, 530-554.

[2]   Malcomson, K.G. (1971) Therapy of Meniere’s Disease. Proc R Soc Med., 64, 856-857.

[3]   Ren, H., Yin, T., Lu, Y., Kong, W. and Ren, J. (2015) Intratympanic Dexamethasone Injections for Refractory Meniere’s Disease. International Journal of Clinical and Experimental Medicine, 8, 6016-6023.

[4]   Trune, D.R., Kempton, J.B. and Gross, N.D. (2006) Mineralocorticoid Receptor Mediates Glucocorticoid Treatment Effects in the Autoimmune Mouse Ear. Hearing Research, 212, 22-32.

[5]   Jang, C.H., Cho, Y.B., Choi, C.H., Park, S.Y. and Pak, S.C. () Effect of Topical Dexamethasone on Sensorineural Hearing Loss in Endotoxin-Induced Otitis Media. In Vivo, 21, 1043-1047.

[6]   Parnes, L.S., Sun, A.H. and Freeman, D.J. (1999) Corticosteroid Pharmacokinetics in the Inner Ear Fluids: An Animal Study Followed by Clinical Application. Laryngoscope, 109, 1-17.

[7]   Newman, C.W., Jacobson, G.P. and Spitzer, J.B. (1996) Development of the Tinnitus Handicap Inventory. Archives of Otolaryngology—Head and Neck Surgery, 122, 143-148.

[8]   McCombe, A., Baguley, D., Coles, R., McKenna, L., McKinney, C. and Windle-Taylor, P. (2001) Guidelines for the Grading of Tinnitus Severity: The Results of a Working Group Commissioned by the British Association of Otolaryngologists, Head and Neck Surgeons, 1999. Clinical Otolaryngology & Allied Sciences, 26, 388-393.

[9]   Committee on Hearing and Equilibrium Guidelines for the Diagnosis and Evaluation of Therapy in Menière’s Disease (1995) American Academy of Otolaryngology-Head and Neck Foundation, Inc. Otolaryngology—Head and Neck Surgery, 113, 181-185.

[10]   Bird, P.A., Murray, D.P., Zhang, M. and Begg, E.J. (2011) Intratympanic versus Intravenous Delivery of Dexamethasone and Dexamethasone Sodium Phosphate to Cochlear Perilymph. Otology and Neurotology, 32, 933-936.

[11]   Barriat, S., van Wijck, F., Staecker, H. and Lefebvre, P.P. (2012) Intratympanic Steroid Therapy Using the Silverstein MicrowickTM for Refractory Sudden Sensorineural Hearing Loss Increases Speech Intelligibility. Audiology and Neurotology, 17, 105-111.

[12]   Syed, M.I., Ilan, O., Nassar, J. and Rutka, J.A. (2015) Intratympanic Therapy in Meniere’s Syndrome or Disease: Up to Date Evidence for Clinical Practise. Clinical Otolaryngology, 40, 682-690.

[13]   Sanz, E.M., Christiane, Z.L., Manuel, G.J., et al. (2013) Control of Vertigo after Intratympanic Corticoid Therapy for Unilateral Ménière’s Disease. Otology & Neurotology, 34, 1429-1433.

[14]   Alexander, T.H. and Harris, J.P. (2010) Current Epidemiology of Meniere’s Syndrome. Otolaryngologic Clinics of North America, 43, 965-970.

[15]   Jackson, L.E. and Silverstein, H. (2002) Chemical Perfusion of the Inner Ear. Otolaryngologic Clinics of North America, 35, 639-653.

[16]   Lu, L., Dai, Y., She, W., et al. (2010) [Clinical Evaluation of Intratympanic Methylprednisolone Perfusion for Intractable Meniere’s Disease]. Journal of Clinical Otorhinolaryngology, Head, and Neck Surgery, 24, 1012-1015.

[17]   Hillman, T.M., Arriaga, M.A. and Chen, D.A. (2003) Intratympanic Steroids: Do They Acutely Improve Hearing in Cases of Cochlear Hydrops? The Laryngoscope, 113, 1903-1907.

[18]   She, W., Lv, L., Du, X., et al. (2015) Long-Term Effects of Intratympanic Methylprednisolone Perfusion Treatment on Intractable Ménière’s Disease. The Journal of Laryngology & Otology, 129, 232-237.

[19]   Chen, Y., Yang, J., Wu, H., Huang, Q., Wang, Z., Zhang, Z. (2011) [Individual Management of Meniere’s Disease and Evaluation of Functional Outcome]. Journal of Clinical Otorhinolaryngology, Head, and Neck Surgery, 25, 721-725.

[20]   Silverstein, H., Choo, D., Rosenberg, S.I., Kuhn, J., Seidman, M. and Stein, I. (1996) Intratympanic Steroid Treatment of Inner Ear Disease and Tinnitus (Preliminary Report). Ear, Nose & Throat Journal, 75, 468-471, 474, 476 passim.

[21]   Phillips, J.S. and Westerberg, B. (1996) Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd., Chichester.